IVBT (Innovation1 Biotech) Operating Income: $-0.69 Mil (TTM As of Feb. 2024)


IVBT Innovation1 Biotech Inc IVBT
12 GF Score
Price $0.00
View Full Analysis

What is Innovation1 Biotech Operating Income?

Innovation1 Biotech IVBT 12 Operating Income is $-0.69 Mil as of Feb. 2024. GuruFocus rates IVBT with a GF Score™ of 12/100.

Innovation1 Biotech's Operating Income for the three months ended in Feb. 2024 was $-0.15 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.69 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Innovation1 Biotech's Operating Income for the three months ended in Feb. 2024 was $-0.15 Mil. Innovation1 Biotech's Revenue for the three months ended in Feb. 2024 was $0.00 Mil. Therefore, Innovation1 Biotech's Operating Margin % for the quarter that ended in Feb. 2024 was %.

Innovation1 Biotech's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Innovation1 Biotech's annualized ROC % for the quarter that ended in Feb. 2024 was -1,132.08%. Innovation1 Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -60,000.00%.

Innovation1 Biotech  (OTCPK:IVBT) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Innovation1 Biotech's annualized ROC % for the quarter that ended in Feb. 2024 is calculated as:

ROC % (Q: Feb. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2023 ) + Invested Capital (Q: Feb. 2024 ))/ count )
=-0.6 * ( 1 - 0% )/( (0.053 + 0.053)/ 2 )
=-0.6/0.053
=-1,132.08 %

where

Invested Capital(Q: Nov. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.02 - 2.606 - ( 0.006 - max(0, 2.656 - 0.017+0.006))
=0.053

Invested Capital(Q: Feb. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.122 - 2.854 - ( 0.108 - max(0, 2.904 - 0.119+0.108))
=0.053

Note: The Operating Income data used here is four times the quarterly (Feb. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Innovation1 Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2023  Q: Feb. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.6/( ( (0.001 + max(-2.595, 0)) + (0.001 + max(-2.843, 0)) )/ 2 )
=-0.6/( ( 0.001 + 0.001 )/ 2 )
=-0.6/0.001
=-60,000.00 %

where Working Capital is:

Working Capital(Q: Nov. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.011) - (2.606 + 0 + 4.4408920985006E-16)
=-2.595

Working Capital(Q: Feb. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.011) - (2.854 + 0 + 0)
=-2.843

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Innovation1 Biotech's Operating Margin % for the quarter that ended in Feb. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Feb. 2024 )/Revenue (Q: Feb. 2024 )
=-0.15/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Innovation1 Biotech Operating Income Related Terms

Innovation1 Biotech Operating Income Historical Data

* Premium members only.

The historical data trend for Innovation1 Biotech's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation1 Biotech Operating Income Chart

Innovation1 Biotech Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Operating Income
Get a 7-Day Free Trial Premium Member Only -0.63 -0.22 -0.24 -5.25 -1.27

Innovation1 Biotech Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -0.20 -0.18 -0.16 -0.15
IVBT
12GF Score
Innovation1 Biotech Inc IVBT
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovation1 Biotech Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of $-0.69 Mil mean?
Innovation1 Biotech (IVBT) has a Operating Income of $-0.69 Mil as of Feb. 2024. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Innovation1 Biotech and its competitors.
Is Innovation1 Biotech's Operating Income too high?
Innovation1 Biotech's current Operating Income is $-0.69 Mil. Overall, Innovation1 Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Innovation1 Biotech's Operating Income compare to NVIV and PXMD?
Innovation1 Biotech's Operating Income of $-0.69 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Diversified Financial Services company?
A good Operating Income depends on the Diversified Financial Services industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Innovation1 Biotech and its competitors. Innovation1 Biotech's current Operating Income is $-0.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation1 Biotech stock overvalued right now?
Innovation1 Biotech (IVBT) has a current Operating Income of $-0.69 Mil. The current Operating Income is $-0.69 Mil. Innovation1 Biotech's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Innovation1 Biotech (IVBT), the current Operating Income is $-0.69 Mil as of Feb. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation1 Biotech Business Description

Address 7 Grand View Avenue, Somerville, MA, USA, 02143
Innovation1 Biotech Inc is a shell company.
12GF Score

Get the complete analysis for IVBT

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price